DSIP
What Is DSIP (Delta Sleep-Inducing Peptide)? Structure, Origin, Evidence and Status
CL
· 11 min read
A summary of published research, with citations. It states no amount, schedule or route, and makes no claim about what this compound does in a person. Supplied for laboratory research use only.
On this page · 6 sections
DSIP, delta sleep-inducing peptide, is a nine-residue peptide, Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu, characterised in 1977 from the cerebral venous blood of rabbits by a Swiss group looking for a blood-borne sleep factor. The name records that hypothesis, not a confirmed function. Nearly fifty years later no gene encoding it and no receptor for it has been identified. Most of its research is in animals, chiefly rabbits and rats; the human record is a handful of small studies from 1981 to 1992. It is approved nowhere: not by Health Canada, the FDA or the EMA, for any indication.

What is DSIP made of?
Nine ordinary amino acids, with no modified residues and no ring. Schoenenberger and Monnier reported the sequence in their 1977 paper, synthesised it alongside several fragments and two analogues, and found in a double-blind comparison across 58 rabbits that only the full synthetic nonapeptide enhanced delta and spindle patterns on the electroencephalogram (PMID 265572). That single rabbit EEG finding is where the name comes from.
The chemistry is unremarkable. Four of the nine residues are glycine or alanine, two carry acidic side chains, and the single tryptophan at position 1 is the only residue that absorbs usefully in the near ultraviolet. Kovalzon and Strekalova noted that the structure does not resemble any other known peptide family (PMID 16539679), which is part of why its origin has been so hard to trace.
| Property | DSIP |
|---|---|
| Sequence | Trp-Ala-Gly-Gly-Asp-Ala-Ser-Gly-Glu (WAGGDASGE) |
| Also called | Delta sleep-inducing peptide; delta-sleep-inducing peptide |
| CAS number (PubChem) | 62568-57-4 |
| Molecular formula (PubChem) | C35H48N10O15 |
| Molecular weight (PubChem) | About 849 g/mol |
| Origin | Isolated from rabbit cerebral venous blood; characterised in Switzerland, 1977 |
| Evidence stage | Mostly animal; a few small human studies, 1981 to 1992 |
| Regulatory status | No Health Canada, FDA or EMA authorisation found |
In blood, the peptide does not last. Graf and colleagues incubated DSIP in human and rat blood and found it broke down quickly, releasing products that behaved like free tryptophan, while a phosphorylated analogue degraded more slowly. They raised, without settling, the question of whether that difference explained why analogues sometimes gave stronger and more consistent results than DSIP itself (PMID 3628078).
How is DSIP thought to work?
Nobody knows, and that is the central fact about this compound. The usual chain for a neuropeptide runs from a gene, to a precursor protein, to the peptide, to a receptor with a known signalling pathway. For DSIP, every link except the peptide itself is missing.
No gene. Most neuropeptides are cut from a larger precursor encoded by an identifiable gene. No such precursor has been found for DSIP. The closest lead is a database search by Mikhaleva and colleagues, who found the sequence WKGGNASGE, which differs from DSIP at two of its nine positions, inside histone demethylases encoded by the JMJD1B gene, and proposed those proteins as possible precursors of DSIP-like peptides (PMID 21262293). It is a related sequence and a proposal, not the DSIP sequence in a confirmed precursor. The full genetics question is covered in DSIP and genetics.
No receptor. Autoradiography reported binding sites for labelled DSIP on cultured rat brainstem neurones in 1983 (PMID 6688964). In perfused guinea pig brain, Zlokovic and colleagues described a saturable mechanism for DSIP at the blood-brain barrier, inhibited by excess unlabelled peptide and by L-tryptophan (PMID 2547200). Neither is a cloned receptor. Without one there is no assay to screen against and no way to confirm that a reported effect is on-target; why that matters is explained in how peptide receptors work.
An uncertain identity in the body. Antibodies against DSIP do detect material in mammalian tissues and blood, but that is "DSIP-like immunoreactivity", not proof that the nine-residue peptide is what was measured. Kovalzon and Strekalova pointed out that this immunoreactivity sits in hypothalamic neurosecretory nuclei not particularly linked to sleep, reported that in their own earlier work certain synthetic analogues promoted slow-wave sleep in rabbits and rats while DSIP itself did not, and proposed that a still-unidentified DSIP-like peptide may account for much of the activity attributed to DSIP (PMID 16539679).
What has DSIP been studied for?
| Area | Evidence stage | What exists |
|---|---|---|
| Sleep EEG | Animal (rabbit, rat) | The 1977 rabbit finding; later analogue work in which DSIP itself did not reproduce it |
| Insomnia | Small human studies, 1981 to 1992 | Sleep-laboratory studies in tens of patients; one double-blind placebo-controlled study of 16 |
| Circulating levels | Human measurement study | 24-hour plasma immunoreactivity in 12 volunteers |
| Stress responses | Rat | Mainly Russian studies of neuronal activity, gene expression and oxidative markers under stress |
| Experimental stroke and seizures | Rat | Single-group studies, unreplicated |
| Chronic pain | Uncontrolled human pilot | Seven patients, compared with their own baseline |
Sleep is where the name points and where the evidence is weakest. Schneider-Helmert and colleagues reported on synthetic DSIP in insomnia in the Lancet in 1981 (PMID 6112579). The best-designed human study, by Bes and colleagues, followed 16 chronic insomniac patients for five nights in a sleep laboratory in a double-blind, matched-pairs, placebo-controlled design. Two polysomnography measures differed from placebo, but the authors judged the effects weak and possibly due to a chance change in the placebo group, found no change in subjective sleep quality, and concluded that short-term DSIP was not likely to be of major benefit in chronic insomnia (PMID 1299794). The longer history of that literature is in DSIP and sleep.
Circulating levels produced the most awkward result for the name. Friedman and colleagues at the US National Institutes of Health measured plasma DSIP-like immunoreactivity every 30 minutes for 24 hours in 12 healthy volunteers with simultaneous sleep recordings. Levels peaked mid-afternoon and were lowest around 1 a.m., were lower in REM and slow-wave sleep than in wakefulness, did not rise around slow-wave episodes, and tracked body temperature closely (PMID 8175965). If the measured material reflects DSIP, its natural rhythm runs opposite to what "sleep-inducing" implies.
Stress is where most recent work sits, almost all of it from Russian groups in rats. Koplik and colleagues compared DSIP with Deltaran, a formulation combining DSIP with glycine, on neuronal firing in emotion-related brain regions and on survival after experimental cerebral ischaemia in rats (PMID 18975104). These are animal studies from a small number of connected laboratories, without independent replication.
Experimental stroke and seizures each rest on single rat studies. Tukhovskaya and colleagues reported that DSIP-treated rats recovered rotarod performance faster after an experimental focal stroke, while the difference in infarct size was not significant (PMID 34500605). Stanojlović and colleagues studied DSIP alongside valproate in a rat audiogenic seizure model and reported that the combination reduced seizure severity more than either alone, without eliminating epileptiform EEG signs (PMID 17957464).
Pain rests on one pilot study. Larbig and colleagues followed seven patients with migraine, vasomotor headache, tinnitus or psychogenic pain episodes, and compared pain ratings with each patient's own baseline (PMID 6548970). There was no control group, so the design cannot separate the peptide from time, expectation or regression to the mean. How to weigh studies like these is set out in how to read a peptide study.
A search of ClinicalTrials.gov for delta sleep-inducing peptide returns no registered trial of the peptide. None of the human evidence comes from a registered, prespecified trial.
Is DSIP approved anywhere?
Not that we could find. DSIP has no authorisation from Health Canada, the FDA or the EMA, for any indication, and it is not a licensed natural health product in Canada. Russian papers describe Deltaran, a DSIP-and-glycine formulation, in rat research; we could not confirm a registration for it, and a formulation studied in one country's laboratories would not transfer to material sold elsewhere for laboratory research in any case. Status in Canada can be checked in the Drug Product Database, and the general framework is set out in peptides and Canadian law.
What is DSIP commonly confused with?
A sleep hormone. The name reads like a description of function. It is the hypothesis the peptide was isolated under, and the reviews describe that hypothesis as poorly documented and unresolved.
Melatonin. A pineal indoleamine with cloned receptors and a body of randomised trials, not a peptide. The two have never been compared in a study; see DSIP vs melatonin.
DSIP immunoreactor (GILZ). A gene with DSIP in its name. Sillard and colleagues purified a 77-residue porcine brain peptide that an antiserum against DSIP happened to recognise, and reported that its sequence was not related to DSIP (PMID 8375381). The name records an antibody cross-reaction, not a precursor.
DSIP analogues. Phosphorylated and other modified versions were made precisely because DSIP itself was unstable and inconsistent. Findings for an analogue do not describe DSIP, and the reverse is also true.
Supplied here for laboratory use: DSIP. The laboratory's certificate for each lot is linked from its product page. For laboratory research use only.
The findings above describe the compound in the animals and people studied, not any laboratory reagent. Nothing here is medical, dosing, or therapeutic guidance.
Frequently asked questions
Why is it called delta sleep-inducing peptide? Because the 1977 rabbit experiments in which it was characterised reported enhanced delta and spindle activity on the EEG, and the group was searching for a sleep factor in blood. The name was given at isolation. Later work did not establish that the peptide has that function, and its own reviewers have called it a still unresolved riddle.
Does the body make DSIP? Possibly, but it has not been shown. Antibodies against DSIP detect material in blood and brain, yet no gene or precursor protein containing the exact DSIP sequence has been found. Reviewers have proposed that some of that immunoreactivity belongs to a related, still-unidentified peptide.
Has DSIP been tested in randomised trials? Only in small, old studies. The best-designed was a double-blind, placebo-controlled study of 16 insomniac patients published in 1992, whose authors judged the differences weak. ClinicalTrials.gov lists no registered trial of the peptide, and there is no modern trial.
Is DSIP legal in Canada? It has no Canadian authorisation as a drug or as a natural health product. It is sold here as a laboratory research chemical, not for human use. Health Canada states that peptides are generally regulated as prescription drugs.
Selected Research References
- Schoenenberger GA, Monnier M. Characterization of a delta-electroencephalogram (-sleep)-inducing peptide. Proceedings of the National Academy of Sciences of the United States of America. 1977;74(3):1282-1286. pubmed.ncbi.nlm.nih.gov/265572
- Kovalzon VM, Strekalova TV. Delta sleep-inducing peptide (DSIP): a still unresolved riddle. Journal of Neurochemistry. 2006;97(2):303-309. pubmed.ncbi.nlm.nih.gov/16539679
- Graf MV, Saegesser B, Schoenenberger GA. Degradation and aggregation of delta sleep-inducing peptide (DSIP) and two analogs in plasma and serum. Peptides. 1987;8(4):599-603. pubmed.ncbi.nlm.nih.gov/3628078
- Mikhaleva II, Prudchenko IA, Ivanov VT, Voitenkov VB. JmjC-domain-containing histone demethylases of the JMJD1B type as putative precursors of endogenous DSIP. Peptides. 2011;32(4):826-831. pubmed.ncbi.nlm.nih.gov/21262293
- Hösli E, Schoenenberger GA, Hösli L. Autoradiographic localization of binding sites for the delta sleep-inducing peptide ([3H]DSIP) on neurons of cultured rat brainstem. Brain Research. 1983;279(1-2):374-376. pubmed.ncbi.nlm.nih.gov/6688964
- Zlokovic BV, Susic VT, Davson H, et al. Saturable mechanism for delta sleep-inducing peptide (DSIP) at the blood-brain barrier of the vascularly perfused guinea pig brain. Peptides. 1989;10(2):249-254. pubmed.ncbi.nlm.nih.gov/2547200
- Schneider-Helmert D, Graf M, Schoenenberger GA. Synthetic delta-sleep-inducing peptide improves sleep in insomniacs. The Lancet. 1981;1(8232):1256-1257. pubmed.ncbi.nlm.nih.gov/6112579
- Bes F, Hofman W, Schuur J, Van Boxtel C. Effects of delta sleep-inducing peptide on sleep of chronic insomniac patients. A double-blind study. Neuropsychobiology. 1992;26(4):193-197. pubmed.ncbi.nlm.nih.gov/1299794
- Friedman TC, Garcia-Borreguero D, Hardwick D, et al. Diurnal rhythm of plasma delta-sleep-inducing peptide in humans: evidence for positive correlation with body temperature and negative correlation with rapid eye movement and slow wave sleep. Journal of Clinical Endocrinology and Metabolism. 1994;78(5):1085-1089. pubmed.ncbi.nlm.nih.gov/8175965
- Koplik EV, Umryukhin PE, Konorova IL, et al. Delta sleep-inducing peptide and Deltaran: potential approaches to antistress protection. Neuroscience and Behavioral Physiology. 2008;38(9):953-957. pubmed.ncbi.nlm.nih.gov/18975104
- Tukhovskaya EA, Ismailova AM, Shaykhutdinova ER, et al. Delta sleep-inducing peptide recovers motor function in SD rats after focal stroke. Molecules. 2021;26(17):5173. pubmed.ncbi.nlm.nih.gov/34500605
- Stanojlović O, Hrncić D, Rasić A, et al. Interaction of delta sleep-inducing peptide and valproate on metaphit audiogenic seizure model in rats. Cellular and Molecular Neurobiology. 2007;27(7):923-932. pubmed.ncbi.nlm.nih.gov/17957464
- Larbig W, Gerber WD, Kluck M, Schoenenberger GA. Therapeutic effects of delta-sleep-inducing peptide (DSIP) in patients with chronic, pronounced pain episodes. A clinical pilot study. European Neurology. 1984;23(5):372-385. pubmed.ncbi.nlm.nih.gov/6548970
- Sillard R, Schulz-Knappe P, Vogel P, et al. A novel 77-residue peptide from porcine brain contains a leucine-zipper motif and is recognized by an antiserum to delta-sleep-inducing peptide. European Journal of Biochemistry. 1993;216(2):429-436. pubmed.ncbi.nlm.nih.gov/8375381
All products sold by NovaEvum are for research and laboratory use only. They are not intended for human or animal consumption, diagnosis, treatment, cure, or prevention of any disease.
